Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK‐wide real‐world cohort of relapsed myeloma patients.

According to frailty scoring, 72 patients (67.9%) were frail, whilst 34 patients (32.1%) were non-frail. Keywords: frailty; isatuximab; myeloma; pomalidomide; real-world EN frailty isatuximab myeloma pomalidomide real-world 162 167 6 03/30/23 20230401 NES 230401 Multiple myeloma (MM) is primarily a disease of the elderly with 43% of the UK's newly diagnosed (NDMM) patients aged 75 years and over.[1] The highest incidence rates in the UK in both males and females occur in those aged 85-89 years.[1] A structured frailty assessment is needed in elderly myeloma patients in order to individualise treatment decisions.[2] In the relapsed/refractory (RRMM) setting, frailty-based approach to therapy is equally required to devise patient-centred treatment plans, which can reduce the risk of under-treating fit patients and the risk of over-treating frail patients. Baseline patient, disease and treatment characteristics of the different frailty subgroups are fully presented in Table 1. 1 TABLE Baseline patient, disease and treatment characteristics according to frailty subgroups. It is important to bear in mind that comparing the number of episodes between frailty subgroups is limited by the significant difference in cohort size between those subgroups (frail: 72 patients vs. non-frail: 34 patients). [Extracted from the article]